Resources

Your selections:

Clear all

Show Filters

We found 282 resources that match your search.

DAIDS Safety Information Types

Definitions of the types of safety information distributed by DAIDS and methods of distribution.

Document Date:

DAIDS Safety Workshop Durban SA (Nov 2015)

Training workshop in Durban, SA supporting documents: Case Review: All About AEs - Safety Training Expedited Reporting and Assessment - Safety Training Expedited Reporting via DAERS - Safety Training Expedited reporting via DAERS - Case Study

Document Date:

DAIDS Safety Workshop Johannesburg SA (Nov 2015)

Training workshop in Johannesburg, SA supporting documents: Case Review: All About AEs - Safety Training Expedited Reporting and Assessment - Safety Training Expedited Reporting via DAERS - Safety Training Expedited reporting via DAERS - Case Study

Document Date:

DAIDS SAMPLE Informed Consent Template - Stored samples and Associated Health Information for future Research Use 11/5/2012

DAIDS sample Informed consent template, stored samples and associated health information for future research use.

Document Date:

DAIDS Sample Informed Consent Template - Stored Samples for Future Use

Informed Consent documents are in the process of being updated to be compliant with the revised Common Rule.  

Document Date:

DAIDS Therapeutic Research Program Template for Pregnancy Prevention

DAIDS Therapeutic Research Program protocol eligibility criteria for pregnancy prevention.

Document Date:

DAIDS TMF Index Guiding Principles

Document Date:

DAIDS TMF Index Recording

Document Date:

Dapivirine (Microbicide Gel)

Document Date:

Dapivirine (Vaginal Ring)

Document Date:

Dapivirine-Levonorgestrel (Vaginal Ring)

Document Date:

Darunavir (Prezista) Risk List

The following serious side effects have been associated with the use of darunavir given together with ritonavir (RTV). Contact your healthcare provider if you have any of the symptoms of liver problems that are listed and any skin changes with the symptoms listed below.

Document Date:

Darunavir/Cobicistat (Prezcobix) Package Insert

Document Date:

Delamanid (OPC-67683)

Document Date:

Didanosine (Videx EC) Risk List

The following side effects have been associated with the use of didanosine:

Document Date:

Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events - Changes Highlighted

Instructions for using the Table for Grading the Severity of Severity of Adult and Pediatric Adverse Events version 2.0. Changes are highlighted visually within the document.

Document Date:

Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events Changes Highlighted Corrected Version 2.1, July 2017

Instructions for using the Table for Grading the Severity of Adult and Pediatric Adverse Events. Changes highlighted, Corrected version 2.1, July 2017

Document Date:

Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected Version 2.1, July 2017

Instructions for using the Table for Grading the Severity of Adult and Pediatric Adverse Events. Corrected version 2.1, July 2017

Document Date:

Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, v. 1.0

This clarification of the DAIDS Table for Grading the Severity of Adult and Pediatric AE’s provides additional explanation of the DAIDS AE Grading Table and clarifies some of the parameters.

Document Date:

Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, v. 2.0

Instructions for using the Table for Grading the Severity of Severity of Adult and Pediatric Adverse Events version 2.0. This version does not visually show changes with highlighting.

Document Date:

Division of AIDS Safety Office Expedited Adverse Event (EAE) Form

Expedited reporting form for Adverse Events fillable using Microsoft Word.

Document Date:

DNA Mosaic-Tre env DNA Vaccine

Document Date:

DNA-HIV-PT123

Document Date:

DNA-HIV-PT123/NYVAC-HIV-PT1/NYVAC-HIV-PT4 vaccine

Document Date:

Dolutegravir (GSK1349572)

Document Date: